The specific aim of the Boston University Clinical HIV/AIDS Research Training (BU-CHART) Program is to provide rigorous postgraduate training to physicians to enable them to conduct high-quality, ethical HIV/AIDS research focused on disadvantaged populations. BU-CHART will provide specific training in research methods of relevance to study substance abuse, healthcare disparities, and co-morbidities of HIV infection. A particular focus will be formal training in research ethics. The Program Site is comprised of the Boston University School of Medicine (BUSM), Boston University School of Public Health (BUSPH), and Boston Medical Center (BMC), the """"""""safety net"""""""" hospital for the city of Boston. BMC is part of the national Adult AIDS Clinical Trials Group (ACTG), the AIDS Malignancy Consortium, and CDC-sponsored clinical trials of HIV/tuberculosis co-infection. Its investigators have a strong record of sponsored research in HIV epidemiology, HIV/hepatitis C co-infection, HIV and alcohol abuse, adherence, prevention, international HIV research, and HIV interactions with tuberculosis. The proposed BU-CHART Program Director, Dr. Paul Skolnik, has been the PI of two prior NIAID T32 HIV training grants and an NIAID T32 infectious diseases basic research training grant. Dr. Skolnik has a substantial record of serving as mentor for successful trainees, and has ongoing HIV/AIDS-related funding. The Training Program Executive Committee (EC) will consist of Drs. Horsburgh, Skolnik, Samet, Cotton, Felson (who is PI of a K30 award that is partnered with this grant), and Center (the PI of a recently awarded Clinical and Translational Science Award (CTSA). Trainee progress will be monitored through regular meetings of the Program Director with trainees, with oversight by the EC. BU- CHART will be administratively based in the Section of Infectious Diseases (ID), Department of Medicine, BUSM. Two trainees each year will enter a structured program that includes earning the MSc degree at the BUSPH, and conducting a clinical research project under the guidance of a Project Mentor that will form the basis of a thesis submitted as part of the MSc degree. Trainees will also be assigned an Ethics Mentor and write an ethics paper. A member of the EC will be assigned to each trainee as a Senior Mentor. Thus each trainee will have a mentoring team. The primary goal of BU-CHART, on which all efforts are focused, is to transform trainees into independent, physician-investigators in clinical research who have a special focus on research in disadvantaged populations and research ethics.

Public Health Relevance

The BU-CHART program will train doctors to answer important questions about HIV infection through clinical studies and how best to improve people's health through prevention and treatment. BU-CHART will train the next generation of HIV researchers, through interactions with skilled physicians who currently conduct these studies, to meet the challenges of the future related to HIV infection of men, women, and children.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
5T32AI052074-08
Application #
8313965
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Sharma, Opendra K
Project Start
2002-07-01
Project End
2015-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
8
Fiscal Year
2012
Total Cost
$387,397
Indirect Cost
$29,142
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Weinstein, Zoe M; Gryczynski, Gabriela; Cheng, Debbie M et al. (2018) Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend 189:166-171
Barocas, Joshua A; Tasillo, Abriana; Eftekhari Yazdi, Golnaz et al. (2018) Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clin Infect Dis 67:549-556
Barocas, Joshua A; White, Laura F; Wang, Jianing et al. (2018) Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis. Am J Public Health 108:1675-1681
Barocas, Joshua A; Wang, Jianing; White, Laura F et al. (2017) Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Aff (Millwood) 36:2142-2150
Weinstein, Zoe M; Cheng, Debbie M; Quinn, Emily et al. (2017) Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine. Drug Alcohol Depend 170:9-16
Hui, David; Weinstein, Zoe M; Cheng, Debbie M et al. (2017) Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine. J Subst Abuse Treat 79:12-19
Weinstein, Zoe M; Kim, Hyunjoong W; Cheng, Debbie M et al. (2017) Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat 74:65-70
Freiman, J Morgan; Tran, Trang M; Schumacher, Samuel G et al. (2016) Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med 165:345-55
Zanoni, Brian C; Archary, Moherndran; Buchan, Sarah et al. (2016) Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave. BMJ Glob Health 1:e000004

Showing the most recent 10 out of 35 publications